Abstract
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Current Pharmaceutical Design
Title: Inhibition of HIV-1 by Fusion Inhibitors
Volume: 16 Issue: 33
Author(s): Dirk Eggink, Ben Berkhout and Rogier W. Sanders
Affiliation:
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Abstract: The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Export Options
About this article
Cite this article as:
Eggink Dirk, Berkhout Ben and W. Sanders Rogier, Inhibition of HIV-1 by Fusion Inhibitors, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079218
DOI https://dx.doi.org/10.2174/138161210794079218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Follicular Immunology Environment and the Influence on In Vitro Fertilization Outcome
Current Women`s Health Reviews Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Targeting Mitochondrial Biogenesis to Treat Insulin Resistance
Current Pharmaceutical Design Molecular and Biochemical Features of the Mitochondrial Enzyme Ornithine Transcarbamylase: A Possible New Role as a Signaling Factor
Current Medicinal Chemistry Short Peptide Modules for Enhancing Intestinal Barrier Function
Current Pharmaceutical Design GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Potential Genetic Therapies for Acute Lung Injury
Current Gene Therapy Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Human Apolipoprotein C-III – A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins
Cardiovascular & Hematological Disorders-Drug Targets Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems
Current HIV Research Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis
Current Medicinal Chemistry Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomedical Applications of Carbon Nanotubes: A Critical Review
Current Drug Delivery Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Prenatal Stress Enhances Susceptibility to Allergic Diseases of Offspring
Endocrine, Metabolic & Immune Disorders - Drug Targets